Dec 9, 2024, 13:36
Zhen Su: Overcome PD-1 Resistant in Solid Tumor with a Novel Dual T-cell Agonist approach
Zhen Su, CEO at Marengo Therapeutics, shared a post on LinkedIn:
“Overcome PD-1 resistant in solid tumor with a novel dual T-cell agonist approach.
We are presenting our clinical data at ESMO IO 2024 in Geneva, Switzerland next week.
I look forward to meeting friends, collaborators and oncology colleagues to share our clinical trial Phase I learning of Invikafusp Alfa (STAR0602), a first-in-class selective dual T-cell agonist for the treatment of PD-1 resistant solid tumors.
More posts featuring Zhen Su.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 18, 2024, 16:11
Dec 18, 2024, 15:52
Dec 18, 2024, 15:49
Dec 18, 2024, 15:45
Dec 18, 2024, 15:38
Dec 18, 2024, 15:11
Dec 18, 2024, 15:08
Dec 18, 2024, 14:24
Dec 18, 2024, 14:21